ESMO 2023

5 year follow-up

DATO-DX - where is it going?

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Highlights in eBC

My highlights of ESMO23 in metastatic breast cancer

Preoperative checkpointinihition in ER+ disease

The FGFR story in bladder cancer at ESMO23

Lu-PSMA leads forward

When the history of ADC is written: Redefining first-line standard of care in mUC!

New 3rd line therapy for RCC

Clearing up non-clear cell RCC

Early use of enzalutamide in advanced prostate cancer

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

ALINA - immediate change of practice!

Tarlatamab in SCLC

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

My highlights from ESMO 2023

What was the most exciting news at ESMO23?

What is your definition of triple-negative breast cancer?

Anticipated updates and exciting new data for checkpointinhibitors

Data updates for CDK4/6 inhibitors in EBC at ESMO23 - implications for clinical practice

New and better biomarkers are needed!

5 year follow-up

Clinically relevant effect of pembro also in PCR

Analysis of tumour microenvironment and immunophenotype in TNBC

Prognostic score in early HR+/HER2-BC: translational data from ADAPT

MonarchE - trial update

Our guidelines are correct

Negative EFS results from NeoTrip

Ribociclib effective in all subtypes

Neoadjuvant IO - is their new strategy in HR+ breast cancer

Pembrolizumab solidifies as SOC in early-stage TNBC

Detailed view of nodal-negative patients

New data on neoadjuvant immunotherapy

Highlights in eBC

My highlights of ESMO23 in early breast cancer

ER-low corresponds diagnostically to ER-0 breast cancer

Carry-over effects in monarchE confirmed

Use of immunotherapy in the perioperative setting of luminal Her2- BC

Metabolomics reveal differential expression of OMEGA 3 & OMEGA 6 in neoadjuvant treatment

Consolidation of data in early HR+ and triple-negative breast cancer

Preoperative checkpointinihition in ER+ disease

HR+ study with > 20 % PCR

Immunoncology in eBC - triple negative and more?

Punti salienti in eBC

Studio NeoTrip: negativi i risultati

MonarchE - mise à jour de l'essai

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6 nel condizionare la risposta alla terapia neo-adiuvante

Nouvelles données sur l'immunothérapie néoadjuvante

What was the most exciting news at ESMO23?

How to organize a molecular tumorboards in breast cancer?

New targets, new linker, new ADCs - much more to learn with new therapies!

New ADC for metastatic breast cancer?

ADCs in HER2+, HER2low and TNBC - what is the future of ADCs?

Improvement of therapy outcome by app-based patient education

OP seems to be dispensable for super responders

Dato-DXd - new player in advanced luminal disease

Patient-centered molecular medicine - a new approach

DATO-DX - where is it going?

ADC + Immunotherapy - the BEGONIA study paradigm

Duvalumab + Dato-DXd effective

My highlights of ESMO23 in metastatic breast cancer

Our guidelines are correct

TROP2 expression as a potential mechanism of resistance in HER2+ patients

T-DXd also effective for brain metastases

Fulvestran better than anastrozole, but no survival benefit

Robust data from the monarchE

T-DXd - new standard of care for brain mets?

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Highlights in mBC

Benefit for SG even after intensive pretreatment

OP-1250 (Palezestrant) confirms the role of SIRDs after CDK4/6i

TULIP: Trastuzumab duocarmazine without OS benefit

Improved oncological therapy with the smartphone

Still on track for success in HER2-low MBC

New ADC in HR+ disease

Abemaciclib remains consistent in 5-year follow-up

Can surgery be spared following primary systemic therapy?

HS20089 - a novel ADC is coming for TNBC

Even more new generation ADCs in breast cancer?

HER2DX in the PHERgain trial

T-DXd in HER2+ patients with brain metastases

La expresión de TROP2 como potencial mecanismo de resistencia en pacientes HER2+.

Punti salienti in mBC

Lo studio BEGONIA nelle paziento con tumore triplo negativo

HS20089 - un nuovo ADC che si affaccia sulla scenda del TNBC

HER2DX en el estudio PHERgain

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei SERDs dopo le cicline

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par le cancer triple negative

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym leczeniu systemowym?

T-DXd - nowy standard postępowania w przerzutach do mózgu?

Should we use zoledronic acid in all ADT patients?

The optimal timing of RT after radical prostatectomy and QoL data of ENZA therapy in nmHSPC

What is the future of immune therapy in prostate cancer?

Targeted therapy will move forward - but more robust data is needed.

PSMA FORE: Trial and controversies

STAMPEDE. Bone prediction not for everyone - better risk stratification for PCa

IO therapy in metastatic prostate cancer.

When immunotherapy is probably not the best choice: The case of untreated metastatic prostate cancer

RADICALS RT: Trial and controversies

PSMAfore unleashes urooncologic opportunity

Osteoprotection at mHSPC

EMBARK - Quality of Life

EMBARK expands ENZA indication to PCa

Longterm toxicity of adjuvant RT after prostatectomy

Precision medicine at mCRCP

CXCR2 inhibitor in PCa

TITAN: ultra-low PSA = best prognosis

Negative data for pembrolizumab in mHSCPC & mCRPC

Lu-PSMA leads forward

Combination of radioligand therapy with chemotherapy useful

Immunotherapy in metastatic PCa

Brave New World in mCRPC

ENZA P:Trial and controversies

Salvage radiotherapy the new standard

Embark without fear

Early use of enzalutamide in advanced prostate cancer

Big data and AI prediction tools

EMBARK och livskvalitet

Big Data och AI för prediktion vid prostatacancer

STAMPEDE data. Skelettstärkande och riskstratifiering.

Cuando la inmunoterapia probablemente no es la mejor elección: El caso del cancer de próstata avanzado en pacientes no seleccionados

CXCR2 hämmare och prostatacancer

Immunterapi vid prostatacancer

Part 2: New standard of care in first line urothelial cancer!

FGFR inhibitors and ADC combinations in urothelial cancer - new options for the future?!

Part1: New standard of care in first line urothelial cancer?!

FGFR inhibitors: What is the best scenario for this family of compounds?

When the history of ADC is written: Redefining first-line standard of care in mUC!

Chemo-IO establishes itself in the first-line treatment of bladder cancer

Amazing new data in bladder cancer

The FGFR story in bladder cancer at ESMO23

New SoC in firstline bladder cancer

Unique bladder delivery system of gemcitabine herolds remarkable response

DAD, DAD-IO

EV + Pembro as standard of care in first-line therapy of bladder cancer

Στιγμιότυπα για τον καρκίνο των νεφρών και της ουροδόχου κύστης στο ESMO23

Inhibidores de FGFR: Cual es el mejor escenario para esta familia de fármacos?

Reescribiendo la historia de una enfermedad: Nuevo estándar de tratamiento en primera linea en cancer urotelial avanzado

L'histoire du FGFR dans le cancer de la vessie à l'ESMO23

Where does the future therapy go in renal cell carcinoma?

Important new treatment option but only for subset of patients?

Is de-escalating therapy ready for prime-time?

Kidney cancer highlights at ESMO23

Belzutifan - whats next kidney cancer?

Intermittent therapy also possible with TKIs

Clearing up non-clear cell RCC

New mode of action in mRCC - ready for prime time?

New 3rd line therapy for RCC

Belzutifan in later lines of therapy

ALINA - remarkably positive DFS in early-stage ALK+ NSCLC

Moving patients to the neoadjuvant setting in non-metastatic NSCLC

Circulating DNA in AEGEAN trial

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Perioperative IO: OS-benefi from KEYNOTE-671

Substantial improvement in local regional NSCLC

ALINA - a new paradigm in operated NSCLC with ALK-fusion

Neoadjuvant chemo-immunotherapy new standards in early & advanced NSCLC

ALINA - immediate change of practice!

Scene is set for inductive immunotherapy

My highlights from ESMO 2023

Big improvements in early stage and a subset of metatstic NSCLC

Adjuvant alectinib in patients with early-stage ALK+ NSCLC

I miei punti salienti di ESMO 2023

ALINA - un nouveau paradigme dans cBNPC avec la fusion ALK

Perioperatieve chemo-immunotherapie voor alle patienten met resectabel stadium II-IIIB NSCLC?

Les points forts de l'ESMO 2023

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Activating EGFR-mutation - what's coming up?

ESMO2023-impact on everyday practice!

Evolving landscape of ADCs

Rare oncogenic alterations: landmark results on exon 20 insertion & confirming data on RET fusion+ NSCLC

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

Adagrasib + pembrolizumab in patients with KRASG12C mutation

Amivantamab upfront? MARIPOSA trial

PAPILLON - bringing together therapy for the 1st line

Treatment sequences for EGFR-mutated Patients

New standard of care for metastatic EGFR exon 20 insertion mutated NSCLC

Brain metastases – options to improve the systemic treatment

MARIPOSA: Trial and controversies

Do ADCs have brain activity?

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

Big improvements in early stage and a subset of metatstic NSCLC

Amivantamab at progression? MARIPOSA-2 trial

By unanimous decision and still the champion – docetaxel!

Does immunotherapy still have a place in EGFR-positive mNSCLC?

TROPION-Lung01: positive development

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

LIBRETO - a positive study, but was it necessary?

Practice changing results on exon 20 insertion mNSCLC

Changing treatment landscape in EGFR-mutated NSCLC

My highlights from ESMO 2023

MARIPOSA II: Trial and controversies

Substantial improvement in rare alterations

NRG fusions: a new drugable target?

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

I miei punti salienti di ESMO 2023

Les points forts de l'ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Quelles séquences thérapeutiques pour les patients EGFR mutés

L’amivantamab, nouveau standard de traitement pour les EGFR exon 20

Nieuwe standaard voor gemetastaseerd EGFR exon20 insertie gemuteerd NSCLC

Heeft immunotherapie nog een plek in de behandeling van EGFR-positief gemetastaseerd NSCLC?

Amivantamab upfront? MARIPOSA trial

Veränderte Behandlungslandschaft bei EGFR-mutiertem NSCLC

Amivantamab at progression? MARIPOSA-2 trial

Impact of T-cell engagers in SCLC

Tarlatamab in SCLC

New hope for patients with SCLC

A new option in relapsed SCLC

Neue Hoffnung für Patienten mit SCLC

Update on gynaecological cancers

New data on sarkomas

New data on H&N Cancer

Precision oncology in CUP

PCO Therapeutics

Evolution of the revolution - the RUBY trial

First data on luveltamab in multiline treatment for endometrial cancer